In his book The Mathematical Universe, mathematician William Dunham wrote of John Venn’s namesake legacy, the Venn diagram, “No one in the long history of mathematics ever became better known ...

The deal is notable because the U.K.’s cost-effectiveness watchdog initially raised concerns about the durability of the treatment, called Casgevy, in a preliminary ruling last year, saying it ...

Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy Casgevy was approved for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), in ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Prof Bola Owolabi, of NHS England, called it a "monumental step forward", and said the one-off treatment Casgevy, also known as Exa-cel, "holds a very real prospect of a cure". A confidential ...

“Building on the success of CASGEVY’s launch, we continue to broaden our portfolio across oncology, autoimmune and cardiometabolic indications. 2025 promises to be a milestone-rich ...

Vertex offers up to $70,000 in fertility services assistance for patients undergoing Casgevy treatment. HHS claims Vertex’s program incentivizes patients to choose its gene therapy over competitors.

“Building on the success of CASGEVY’s launch, we continue to broaden our portfolio across oncology, autoimmune and cardiometabolic indications. 2025 promises to be a milestone-rich year, with clinical ...

The company's flagship product, Casgevy, developed in collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX), has garnered significant attention as it represents one of the first gene-edited ...